November 2014

NET Cancer Day 2014 - 35W Bridge & Izzy the Islet Cell Zebra

We had our first winter weather event strike on NET Cancer Day, which made travel around the Twin Cities difficult. That didn’t stop Izzy the Islet Cell Zebra from going down to Stone Arch Bridge in Minneapolis to see the 35W bridge over the Mississippi lit up in honor of NET Cancer Day. The sky was odd. It was still snowing around the Metro and it was bitterly cold on

35W Bridge Shows off its Stripes in Support of NET Cancer Day!

NORTHWOODS NETS http://www.northwoodsnets.org info@northwoodsnets.org Press Release Contact: Dawn Marie Peterson Email: dawnmarie@northwoodsnets.org Phone: 612.314.9997 FOR IMMEDIATE RELEASE 7 A.M. CST, November 10, 2014 35W Bridge SHOWS OFF ITS STRIPES in Support of NET Cancer Day MINNEAPOLIS, MN:  If the 35W Bridge appears to be wearing stripes tonight, it is! Monday, November 10 is worldwide NET Cancer Day. NET cancers, caused from rare neuroendocrine tumors or NETS, are the “zebras” of the cancer

NET Cancer Day Selfies!

Northwoods NETS held their support group meeting on November 9th, the day before NET Cancer Day. Our group participated in the “selfie” initiative, which helps gives a face to NET Cancer and the obstacles patients go through to get a proper diagnosis. Here are the Northwoods NETS that participated. If you weren’t able to attend the meeting, but did a selfie, send me an email and I will add you!

NET Cancer Awareness Ideas

This is a list of great ideas to help raise awareness in our communities that Lavonne Levar, one of our pancreatic neuroendocrine patients, has compiled. If you would like to add to the list, drop me a note at I will be glad to add on! Let’s keep the flow going! Bring a NET fact sheet to physicians, with something fun like Zebra balloons, or goodies of some kind wrapped

Results of the largest NET Patient Quality of Life Survey

Results from first global survey of neuroendocrine tumor (NET) patients reveal profound impact of this rare cancer on quality of life The International Neuroendocrine Cancer Alliance (INCA) and Novartis announced the quality-of-life results from the first global survey of patients with neuroendocrine tumors (NETs), a rare type of cancer. Nearly 2,000 patients from 12 countries completed the survey, which was a collaborative effort between INCA and Novartis. The results were